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Abstract
[18F]Fluorodeoxyglucose (FDG) positron emission tomography (PET) is a useful imaging tool in the evolving
management of patients with colorectal carcinoma. This technique is able to measure and visualize metabolic changes
in cancer cells. This feature results in the ability to distinguish viable tumor from scar tissue, in the detection of
tumor foci at an earlier stage than possible by conventional anatomic imaging and in the measurement of alterations
in tumor metabolism, indicative of tumor response to therapy. Nowadays, FDG-PET plays a pivotal role in staging
patients before surgical resection of recurrence and metastases, in the localization of recurrence in patients with
an unexplained rise in serum carcinoembryonic antigen and in assessment of residual masses after treatment. In
the presurgical evaluation, FDG-PET may be best used in conjunction with anatomic imaging in order to combine
the benefits of both anatomical (CT) and functional (PET) information, which leads to significant improvements in
preoperative liver staging and preoperative judgment on the feasibility of resection. Integration of FDG-PET into the
management algorithm of these categories of patients alters and improves therapeutic management, reduces morbidity
due to futile surgery, leads to substantial cost savings and probably also to a better patient outcome. FDG-PET also
appears to have great potential in monitoring the success of local ablative therapies soon after intervention and in the
prediction and evaluation of response to radiotherapy, systemic therapy, and combinations thereof. This review aims
to outline the current and future role of FDG-PET in the field of colorectal cancer.
Keywords: FDG; PET; colorectal cancer; recurrent disease; unexplained CEA rise; liver metastases; unresactable disease;
response monitoring.
Introduction
Colorectal cancer is the second leading cause of cancer-
related deaths in the Western world and continues to
be a major health problem worldwide. The cumulative
lifetime risk is approximately 5%, the incidence in the
Western world is 50/100,000 and the 5-year survival
rate nowadays is approximately 55% [1]. The prognosis
of this disease has improved substantially with the
introduction of hepatic resection for treatment of isolated
liver involvement and with the introduction of effective
chemotherapeutic agents [2–4]. [18F]Fluorodeoxyglucose
(FDG) positron emission tomography (PET) is a useful
imaging tool in the evolving management of patients
with colorectal cancer. FDG-PET localizes tumors by
identifying cells in the body that have increased glucose
uptake and metabolism. FDG is transported into cells
analogous to glucose and is converted to FDG-6-
phosphate. This metabolite is trapped in the cell, as it
will not be processed in the glycolytic pathway and
hence will accumulate preferentially in those cells with
high glucose uptake, such as tumor cells. Although the
optimal use of FDG-PET in colorectal cancer continues
to emerge, this comprehensive review aims to discuss
its current and potential future applications in the
management of patients with colorectal cancer. The
literature is reviewed on the established role of FDG-
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PET in distinguishing fibrosis and scar tissue from viable
tumor in residual masses of rectal cancer, localization
of recurrence in patients with an unexplained rise in
serum carcinoembryonic antigen (CEA), staging before
surgical resection of recurrence and/or metastases, and
on its emerging role in the prediction and evaluation of
treatment response, such as monitoring of radiotherapy
and multimodality treatment response in primary rectal
cancer, response after local ablative therapy of liver
metastases and chemotherapy response in advanced
colorectal cancer. FDG-PET in the initial preoperative
staging of newly diagnosed colorectal cancer is not
discussed, since there is no established role for the
systematic use of PET in this part of the management
process, due to its poor sensitivity regarding detection of
early tumor spread to regional lymph nodes [5].
Detection of recurrent disease
Recurrent rectal cancer in residual masses
Surgery is the key to cure for patients with rectal
cancer. In the past, local recurrence rates after conven-
tional surgery averaged 30% and varied considerably
between institutions from 15% to 45% [6–8]. Recently,
total mesorectal excision with or without preoperative
radiotherapy has played a major role in reducing the rates
of local recurrence to 5–11% [9–11]. One reason for this is
the higher frequency of complete resection of the tumor
together with its lymphatic and venous drainage that is
achieved by complete removal of the mesorectum [12,13].
During the past decades a broad spectrum of treatment
modalities have been examined such as postoperative
chemoradiotherapy with different 5-fluorouracil (5FU)
based schedules, short-term preoperative radiotherapy (5
G/day in 5 days), prolonged preoperative radiotherapy
(alone or in combination with 5FU based regimens
or with new drugs), and intraoperative radiotherapy in
primary disease, and combinations of drugs in patients
with metastatic disease; all aiming at improvement in
standards of care, ameliorating quality of life with
better local control, fewer complications, and improved
survival [14].
After resection of the primary tumor most patients will
develop a fibrotic mass in the presacral surgical bed, and
external beam radiation therapy causes an inflammatory
reaction in the pelvic tissues which induces thickening of
the perirectal fascia [15,16]. These changes might compli-
cate the detection of pelvic recurrence with ultrasound,
CT or MRI, since these techniques have limited ability to
distinguish scar from viable tumor. It appears that FDG-
PET does not demonstrate this limitation. The first reports
on the clinical application of FDG-PET in colorectal
cancer addressed the differentiation between scar tissue
and local recurrence in rectal cancer [17,18]. There is
evidence that FDG-PET is superior to CT scanning for
assessing disease activity. FDG-PET has been noted
to have a sensitivity of 84–100% and a specificity of
80–100% in the detection of local recurrence and the
accuracy ranges from 74% to 96% [16,19–29]. The required
interval for postradiotherapy evaluation with FDG-PET
has not been studied systematically. It is, however,
generally accepted that FDG activity at 6 months after
completion of radiation therapy most likely represents
tumor recurrence. Increased FDG uptake immediately
after radiotherapy may be due to inflammatory changes
and is not always associated with residual tumor [19,30,31].
Approximately 25% of FDG uptake can accumulate
in non-tumor tissues such as macrophages, neutrophils,
fibroblasts, and granulation tissue [32]. Obviously, a true
radiation-induced reduction in glucose utilization occurs
due to tumor cell loss [33]. However, a short-lived
reversible decrease in glucose metabolismmay also occur
just after radiotherapy, due to the so-called stunning
of tumor cells [34]. This phenomenon can mimic actual
cytotoxic therapy effects, although only temporarily.
As early as 1991, Haberkorn et al. showed that it is
not possible to distinguish between proliferation, repair,
inflammation, and residual viable tumor cells shortly
after radiotherapy. In this study, a significant decrease in
FDG uptake was not observed in 50% of patients despite
good palliative effects [30]. This was confirmed by another
study performed in the same institute, and the authors
postulated that FDG-PET evaluation is not reliable within
3 months after radiotherapy [31]. This hypothesis was
also supported by a retrospective case-controlled study
performed by Moore et al. [19]. They reviewed the records
of 60 surgically resected rectal cancer patients who
underwent FDG-PET at least 6 months after radiotherapy.
A sensitivity of 84%, a specificity of 88%, an overall
accuracy of 87%, a positive predictive value of 76% and
a negative predictive value of 92% were observed for
the detection of local recurrence. The positive predictive
value and accuracy improved in scans performed more
than 12 months after radiotherapy. They postulated that
the reliability of FDG-PET improves with time, probably
due to resolution of early postradiation inflammation.
Accurate detection of locoregional recurrence may be
hindered by a marked distortion of the normal pelvic
anatomy [21,25]. After abdominoperineal resection, the
empty rectal fossa may result in displacement of other
pelvic organs. For instance, the urinary bladder tends to
move backwards to a presacral or precoccygeal location.
Furthermore, the empty fossa may be occupied by
the seminal vesicles, uterus, or the small bowel. This
altered pelvic anatomy may influence the interpretation
of FDG-PET images, especially in the differentiation
between tumoral and physiologic FDG uptake in the gas-
trointestinal or genitourinary tract. Even-Sapir et al. [25]
reported that physiologic FDG uptake in displaced pelvic
organs was the most common cause for false-positive
interpretation of FDG-PET findings. Keogan et al. [21]
suggested appropriate hydration and prescan voiding,
bladder catheterization, and registration of anatomic and
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metabolic images as ways to overcome this problem.
Therefore, there may be an important role for integrated
PET/CT, which combines the benefits of the two imaging
modalities and provides the clinician with simultaneous
metabolic and anatomic imaging information [25]. Even-
Sapir et al. [25] studied 62 patients and found presacral CT
abnormalities in 30 patients (48%). Of these, seven (23%)
abnormalities appeared to be malignant. For detection of
malignancy in presacral residual masses with PET/CT,
they reported a sensitivity, specificity, positive predictive
value, and negative predictive value of 100%, 96%, 88%,
and 100%, respectively. In this study PET/CT images
also provided information concerning the involvement
of pelvic structures, which was clinically relevant in
selecting an appropriate surgically approach.
Unexplained carcinoembryonic antigen rise
Although the ideal postoperative follow-up regimen for
asymptomatic patients after curative colorectal cancer
resection remains undefined, clinicians often use a
combination of history, physical examination, imaging,
and laboratory tests including measurement of the serum
tumor marker carcinoembryonic antigen (CEA) [15].
Elevated serum CEA levels are detected in two-thirds
of patients with recurrence of colorectal carcinoma and
have been associated with a 3–9-month median lead-
time in detection of recurrence over anatomic imaging
modalities [5,35–39]. Measurement of serum CEA every
2–3 months for at least 2 years after surgery has
been advocated [35,40–42]. Such intensive follow-up after
primary curative treatment may detect more cancer
relapses that are amenable to curative resection. Two
meta-analyses reported that intensive follow-up improves
overall survival and reduces absolute mortality by 9–
13% [43,44]. Although serum CEA may detect recurrence,
it does not identify the site of recurrence. Patients
with rising serum CEA levels without detectable disease
on morphological imaging pose a clinical challenge.
Abnormal serum CEA levels are also observed in a
variety of benign conditions, such as liver diseases,
bowel diseases, smoking, and renal failure [35]. The
problem with false-positive serum CEA elevation is
that it may lead to unnecessary imaging or even
surgery with associated morbidity. Several studies have
demonstrated the value of FDG-PET in patients with
rising serum CEA levels and no identifiable lesions
on conventional imaging [23,27,45–53]. Fletcher concluded
that a serum CEA >10 ng/ml was rarely caused by
benign conditions [54]. Liu et al. [35] reported that the
cumulative survival of patients with an unexplained
serum CEA level >25 ng/ml was significantly worse
than that of patients with levels <25 ng/ml. They
suggested a serum CEA cutoff value of 10 ng/ml
as an indication for FDG-PET. An increase in CEA
level is also strongly associated with tumor recurrence
with a reported specificity of 70–84%. Its sensitivity is
approximately 80%, but is not as high for locoregional
recurrence and pulmonary metastases as it is for liver
metastases [5]. In asymptomatic patients with rising serum
CEA levels without abnormal findings of conventional
workup, the sensitivity for detection of recurrence with
FDG-PET has been reported as 79–100%, specificity as
50–83%, and accuracy as 74–93% [22,35,45–49]. Positive
predictive values ranged from 89% to 95% and negative
predictive values from 85% to 100% [22,45,47]. In a
study of 28 patients with a rising serum CEA, negative
imaging and second look laparotomy, the results of
FDG-PET and CEA scintigraphy scans (99mTc-labeled
arcitumomab) were analyzed as predictors of correct
selection of patients for resection [48]. Ninety-four percent
of patients had biopsy confirmation of recurrence.
Disease was unresectable in 38% of these recurrences.
PET correctly predicted unresectable disease in 90% of
cases, whereas CEA scintigraphy scan failed to predict
any. PET correctly predicted resectable disease in 81%
and CEA scintigraphy in only 13%. The impact of FDG-
PET on management of patients with a rising serum
CEA after primary curative treatment has also been
examined [47,55,56]. In a series of 58 patients, 34 (59%)
had a management change after FDG-PET, including
18 (31%) who underwent a curative resection and 16
(28%) who were treated with systemic chemotherapy [56].
Similar findings have been reported by Flamen et al. [47].
The impact on management in the study of Liu et al. [55],
however, was even higher (68%). The positive impact
of FDG-PET on management decisions in this clinical
scenario is evident. FDG-PET is recommended for
patients with an otherwise unexplained increase of serum
CEA level after primary curative treatment of colorectal
carcinoma, provided they are fit to undergo salvage
surgery.
Staging of recurrence irrespective of CEA or
tumor site
Several studies have described the additional value of
FDG-PET imaging over anatomical imaging in recurrent
colorectal cancer [20,22,26–28,57–69]. Metabolically active
tumors can be detected before a morphologic change is
noted on anatomical imaging. Overall, FDG-PET was
more accurate compared to CT scanning. A meta-analysis
of 11 clinical reports with 577 patients showed an overall
sensitivity of 97% and specificity of 76% for FDG-PET
detecting recurrent colorectal cancer [63]. In addition, a
comprehensive review of the PET literature (2244 FDG-
PET studies) has reported a weighted average for FDG-
PET sensitivity and specificity of 94% and 87%, respec-
tively, compared with 79% and 73% for CT scanning [70].
Whiteford et al. [26] reported that the sensitivity of FDG-
PET imaging for detection of mucinous adenocarcinoma
(58%, n = 16) was significantly lower than for non-
mucinous adenocarcinoma (92%, n = 93) (p = 0.005).
They proposed that this lower sensitivity is due to the
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relative hypocellularity of these tumors. Similar findings
(sensitivity of 41%) have been reported in a subsequent
series of 22 patients [71].
Staging before surgical resection of colorectal
liver metastases
Liver metastases are the main cause of death in patients
with colorectal cancer. Approximately 20% of patients
already have liver metastases at the time of detection
of the primary tumor, and another 25% will develop
metastatic lesions during the following 4 years [5,72].
Without any treatment, the median survival after the
detection of liver metastases is approximately 9 months,
depending on the extent of the disease at the time
of diagnosis [73]. For patients with recurrent disease
confined to the liver, resection of the metastases is the
treatment of choice and can result in a 5-year survival
of more than 40%, depending on the selection criteria
for surgery [74–76]. With the exception of lung metastases,
the presence of extrahepatic disease, however, typically
precludes surgery as does the involvement of major blood
vessels or extensive bilobar liver disease, which would
either preclude negative resection margins or would result
in inadequate hepatic reserve. Therefore preoperative
staging should concentrate on careful evaluation of
extrahepatic disease and precise delineation of all liver
lesions with regard to number and position to vital
anatomic structures. This strongly supports the need for
more effective preoperative imaging to improve staging
in order to avoid futile surgery. Synchronous metastases,
multiple metastases or bilobar disease once considered
as absolute contra-indications for resection, currently do
not preclude resections with curative intent per se [1]. The
selection of patients for surgical resection of colorectal
liver metastases, however, still poses a significant
clinical problem. A significant number of patients (10–
25%) considered suitable for surgical resection of liver
metastases appear to have unresectable disease identified
during laparotomy [72]. Moreover, 60% of patients will
develop recurrent tumor after successful hepatic resection
within 3 years, indicating that many of the patients
must have harbored unrecognized tumor foci either in
the liver or in extrahepatic areas at the time of liver
resection [72,77,78].
Whole body survey and analysis of metabolic activity,
as performed with FDG-PET has emerged as a pivotal
diagnostic tool in patients with suspected recurrent
disease in the liver and has proven to be an accurate
diagnostic technique for determining whether patients
are suitable candidates for curative resection. A meta-
analysis of Kinkel et al. documented the superiority
of FDG-PET over ultrasound, CT, and MRI, and
showed that FDG-PET might be the most sensitive
imaging modality for detection of hepatic metastases of
gastrointestinal cancer [58]. A more recent meta-analysis
of 61 studies showed a sensitivity of 95% for FDG-
PET on a per-patient basis, which was significantly better
compared to CT scanning (65%) and magnetic resonance
imaging (MRI) (76%) [57]. Very recently, the meta-
analysis of Wiering et al. [72] showed a pooled sensitivity
and specificity of 88% and 96%, respectively, for hepatic
disease, and 92% and 95%, respectively, for extrahepatic
disease. For CT scanning, the pooled sensitivity and
specificity were 83% and 84%, respectively, for hepatic
lesions, and 61% and 91%, respectively, for extrahepatic
lesions.
FDG-PET as a complementary staging method has
been shown to significantly alter and improve therapeutic
management in 14–65% of patients with colorectal liver
metastases, especially by detecting unsuspected extrahep-
atic disease in 13–36% [16,20,22,23,28,45,52,53,59–61,78–86]. A
prospective study by Ruers et al. [78] demonstrated a
change in clinical management in 20% of patients (10
out of 51 patients) being evaluated as candidates for
resection of colorectal liver metastases, especially by
detecting unsuspected extrahepatic disease. In a another
prospective study of 102 patients with suspected or
confirmed regional recurrence of colorectal cancer, FDG-
PET influenced management decisions in 59% of cases.
The high impact on treatment planning in this study was
also predominantly due to avoiding surgery in patients
with widespread disease [27]. Huebner et al. reported in
a meta-analysis that the pooled change-in-management
was calculated at 29% (95% confidence level, 25–
34%) [63]. The pooled change in-management in the meta-
analysis ofWiering et al.was 32% (range 20–58%) [72]. A
comprehensive review of the PET literature has reported a
weighted average change of management related to FDG-
PET findings in 32% of 915 patients [70]. The results of
these numerous studies brought about a broad consensus
that FDG-PET has a clear role in the re-staging of
recurrent colorectal cancer.
Although survival is not an endpoint for a diagnostic
test, Strasberg et al. [87] estimated the survival of patients
who underwent FDG-PET imaging in their preoperative
evaluation for resection of hepatic metastases. The
Kaplan–Meier estimate at 3 years was 77% for overall
survival and 40% for disease-free survival. Both per-
centages were higher than those previously reported [88].
Fernandez et al. showed that FDG-PET imaging prior
to surgical resection improved the 5-year survival rate
compared to historical controls [89]. This improvement
in survival is certainly mainly due to the so-called
Will Rogers phenomenon or the phenomenon of stage
migration due to more careful staging of cancer [90].
Although FDG-PET provides highly relevant infor-
mation for patient management, it does not substitute
the excellent anatomical imaging provided by spiral CT
scanning. CT scanning provides the detailed anatomic
information that is required for an optimal planning of
hepatic resection. Resectability of liver metastases is
generally determined by the extent of liver involvement
and the specific relation of metastases to anatomic
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structures, such as the hepatic veins and the biliary
tract [1]. Thus, in patients with suspected hepatic metas-
tases from colorectal cancer, FDG-PET may be best
used in conjunction with anatomic imaging. Integrated
PET/CT modalities, that combine the benefits of both
anatomical (CT) and functional (PET) information and
allow optimal coregistration of images, may lead to a
significant improvement of preoperative liver staging and
preoperative judgment on the feasibility of resection [91].
A study of 45 patients [92] reported that PET/CT
imaging increases the accuracy and certainty of locating
lesions. The frequency of equivocal and probable lesion
characterization was reduced by 50% with PET/CT
compared with PET alone, the number of definite
locations was increased by 25%, and the overall correct
staging increased from 78% to 89%.
These advances in imaging technologies bring another
challenge to physicians at times when it is also important
to provide care at an acceptable cost. Increasing cost-
effectiveness and decreasing the number of invasive
procedures are currently two of the major trends in health
care. Including FDG-PET in the evaluation of patients
with recurrent colorectal carcinoma has been shown to
be cost-effective in a study using clinical evaluation
of effectiveness with modeling of costs and studies
using decision tree sensitivity analysis [22,93–95]. Zubeldia
et al. [94] found an average expected surgical cost per
patient of $16,278 when FDG-PET was used, compared
to $21,547 for conventional management, a net saving of
$5269. In a prospective study involving 115 patients who
underwent CT and FDG-PET scanning for diagnosis or
staging of recurrent colorectal carcinoma Valk et al. [22]
found per-patient savings of $3003. Their smaller cost
reductions may be explained by the inclusion of pelvic
($12,916) and lung ($15,508) resection in addition to
hepatic resection ($20,668). The analysis of Zubeldia
considered only hepatic resection [94]. So, integration of
FDG-PET into the presurgical evaluation of patients
with potential resectable hepatic metastases alters and
improves therapeutic management, reduces morbidity
due to futile surgery, leads to substantial cost savings and
probably also to a better patient outcome. Randomized,
controlled clinical trials should be performed to confirm
the actual impact of FDG-PET on overall survival, in
order to further strengthen the role of FDG-PET in the
management of colorectal liver metastases.
Prediction and evaluation of treatment
response
The current definition of tumor response is based on the
measurement of changes in tumor size as determined
with morphological imaging methods. According to the
response evaluation criteria in solid tumors (RECIST)
criteria a tumor is classified as responding when the
largest diameter of the tumor decreases by at least
30% [96]. Despite the widely accepted practice of using
these criteria, it is important to realize that a 30%
decrease of tumor size is an arbitrary convention, and
is not based on outcome studies. In fact, the correla-
tion between morphologic tumor response and patient
outcome is rather weak [97]. Moreover, morphological
imaging techniques have limitations in assessing the
therapeutic effect, since changes in tumor size lag behind
the biologic response to therapy, which is considered a
problem in early response monitoring. Besides, residual
non-tumoral masses may persist, despite the fact that
disease activity may have completely resolved after
successful therapy. Furthermore, the introduction of
molecular-targeted agents such as the angiogenesis
inhibitor bevacizumab, requires new surrogate end points
for monitoring therapeutic effects since they have
different biological effects compared to classic cytotoxic
chemotherapy. These new agents inhibit the growth
of new blood vessels in cancer tissue, which does
not immediately result in dissolution of tumor masses,
and thus poses new demands on imaging modalities.
When anticancer therapy becomes more individualized,
it is increasingly important to identify response to
therapy as early as possible. Early identification of
non-responders may allow physicians to spare these
patients the morbidity (and costs) of systemic treatment.
Several studies performed on tumors other than colorectal
carcinoma have already confirmed the hypothesis that
changes in tumor glucose metabolism early in the course
of treatment predict therapy outcome and long-term
prognosis [98–102]. So far, in colorectal carcinoma only
studies in small series of patients have been performed,
and the interval between onset of antitumor therapy
and FDG-PET evaluation, as well as the method of
quantification differ per study. The optimal method
for quantification has not yet been defined and the
threshold set for response depends on multiple variables
such as tumor type, type of therapy and interval after
onset of therapy. Therefore, further studies are needed
before definite conclusions can be drawn. This section
reviews the currently available literature on radiotherapy
and/or chemotherapy response monitoring in colorectal
carcinoma.
Preoperative multimodality and radiotherapy
treatment response evaluation in primary
rectal cancer
In rectal cancer, preoperative chemoradiotherapy is used
in advanced T3 and T4 tumors in the attempt to down-
stage the disease, in order to reduce the risk of local recur-
rence and to allow sphincter preserving tumor resection
in selected cases [103,104]. FDG-PET may have a role in
preoperative multimodality treatment response evaluation
and in a preoperative strategy aimed at identifying
patients most suitable for sphincter preserving surgery.
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Amthauer et al. [34] performed FDG-PET and endorectal
ultrasound in 20 consecutive patients with locally
advanced primary rectal cancer before and 2–4 weeks
after completion of neoadjuvant chemoradiotherapy in
combination with regional hyperthermia. Reduction in
tumor standardized uptake value (SUV) was significantly
greater in (histopathologically confirmed) responders
compared to non-responders. Using a minimum postther-
apeutic SUV reduction of 36% to define response, FDG-
PET revealed a sensitivity of 100% and a specificity of
86%. The corresponding positive and negative predictive
values were 93% and 100%, respectively, which was
significantly better than for endorectal ultrasound. In
a similar study performed in the same institute, 23
patients underwent FDG-PET, as well as CT scanning
and MRI [105]. The results suggested that FDG-PET
was also superior to both CT and MRI. Guillem
et al. [106] assessed the response in primary rectal cancer
to preoperative radiation and 5-FU-based chemotherapy
in 15 patients. FDG-PET was obtained before and at
4–5 weeks after completion of chemoradiotherapy. All
patients demonstrated a pathologic response, which was
predicted in 100% of cases by PET, compared with 78%
by CT. They also demonstrated that estimation of rectal
cancer response to preoperative chemoradiotherapy by
FDG-PET predicts long-term clinical outcome, a finding
that has recently been corroborated by others [107,108].
It is striking that the confounding radiotherapy-induced
effects, as discussed earlier, have less impact on the
results of FDG-PET if it is combined with chemotherapy
and/or regional hyperthermia. This implies that the
nature of the combination of treatment modalities for
neoadjuvant therapy is important in the timing of FDG-
PET evaluation. Further studies are required to ascertain
the exact sequence of time-dependent (radio)biological
effects during neoadjuvant multimodality treatment.
For induction radiotherapy alone, it has not yet been
sufficiently investigated whether FDG-PET could play a
role in the preoperative radiotherapy response assessment
of primary rectal cancer. The generally accepted interval
of at least 6 months for FDG-PET evaluation after
adjuvant radiotherapy is not applicable in a neoadjuvant
setting. Probably due to these expected confounding
radiotherapy-induced effects on FDG uptake only one
study on this subject has been performed. This study
of Schiepers et al. [33] investigated nine patients with
rectal cancer before and 2–3 weeks after radiotherapy.
They observed an overall decrease of glucose utilization
with a reduction in SUV after neoadjuvant treatment
of 65% in comparison to the pretherapy value, which
correlated to reduction of tumor burden and cell death.
The authors concluded that they could discriminate as
early as 2 weeks after radiotherapy between successfully
and unsuccessfully treated tumors with an accuracy
of 80%. These surprising results call for systematic
investigation of the required interval for postradiotherapy
evaluation with FDG-PET.
Monitoring response after local ablative
therapy of liver metastases
For patients with colorectal liver metastases surgical
resection offers the best chances for cure. In most patients
with colorectal liver metastases, however, resection
cannot be performed. When this is caused by the number
and/or localization of metastases, local ablative tech-
niques such as cryosurgery or radiofrequency ablation
may offer an alternative treatment that produces localized
intrahepatic tumor destruction and possibly results in
a prolongation of survival. A prospective randomized
trial on the impact of radiofrequency ablation versus
chemotherapy (CLOCC) is on-going.
Different morphological imaging techniques have been
used to facilitate the intraoperative localization. However,
during the process of local ablation the destruction
process cannot easily be ascertained with intraoperative
ultrasound imaging because of the hyperechogenicity
that is induced within the treated area [109]. Furthermore,
evaluation with CT scanning or MRI of residual
tumor after the ablation procedure is limited because
posttreatment hyperemia or tissue regeneration may
result in contrast enhancement in the periphery of
the ablative necrosis [110]. This can lead to either a
delayed diagnosis of treatment failure or to confusion
between incomplete local ablative treatment and the
occurrence of new metastases in regions adjacent to the
treatment site. Several studies described the feasibility
of FDG-PET scanning in the surveillance of these
patients [55,111–113]. It appears to have great potential
in identifying residual tumor soon after local ablative
treatments. In a prospective study of 23 patients with
a mean follow-up of 16 months, Langenhoff et al. [111]
showed that FDG-PET has a positive predictive value
of 80% (4/5 lesions) and a negative predictive value for
the detection of local treatment failure of 100% (51/51
lesions) when performed less than 3 weeks after the
ablative procedure. There was one false-positive FDG-
PET caused by abscess formation in a lesion treated
with radiofrequency. In all patients the time point of
detection of recurrence by FDG-PET was considerably
earlier compared to the detection by CT scanning.
Donckier et al. [113] reported on the value of FDG-
PET performed at 1 and 4 weeks after local ablative
treatment. Residual hypermetabolism in the periphery
of ablated sites detected by FDG-PET correlated well
with incomplete tumor destruction in 4/28 lesions. CT
imaging performed at the same time failed to demonstrate
residual hypervascularized lesions in these patients. After
a median follow-up of 11 months, none of the 24 FDG-
PET negative postablative lesions had developed a local
recurrence. A more recent study [112] performed in 43
patients with 104 ablated lesions, CT scanning after
treatment did not predict local treatment failure, whereas
FDG-PET within 3 weeks after local ablative treatment
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predicted 6/7 local recurrences. One local recurrence
was detected on FDG-PET 3 months after treatment.
The negative predictive value of FDG-PET at 3 months
was 100%. Since FDG-PET showed one false positive
result due to focal infection, the positive predictive
value was 88%. The data presented here indicate that
FDG-PET could play a central role in optimizing the
use of local ablative treatment of liver metastases as it
recognizes early incomplete tumor ablation that is not
detectable by CT scanning. FDG-PET determines the
need for further investigations and guides the reading
of the CT scan, which on its own appears difficult to
interpret in the early period after local ablative therapy.
The combined information of FDG-PET and CT scans
offers the opportunity to re-treat tumors at an early stage.
Chemotherapy response monitoring in
advanced colorectal cancer
There are four reports suggesting that FDG-PET can
predict response to chemotherapy in patients with
irresectable colorectal cancer liver metastases. Findlay
et al. [114] studied 18 patients on 5-FU chemotherapy
before and at 1–2 and 4–5 weeks. Responding lesions
had a greater reduction in FDG uptake compared to
the baseline value than non-responding lesions (−33%
vs. −1%). The 4–5-week tumor-to-liver ratio was able
to discriminate response from non-response in both a
lesion-by-lesion assessment as well as in an overall
patient response assessment with a sensitivity of 100%
and specificities of 90% and 75%, respectively. A clear
correlation was observed between the reduction of tumor
metabolism 5 weeks after the initiation of chemotherapy
and treatment outcome, which was not observed at 1–2
weeks on treatment. These results show the importance
of a correct timing of FDG-PET after the onset of
chemotherapy. The authors mention the so-called flare
phenomenon that occurs 1–2 weeks after the initiation
of chemotherapy, which can be observed as a marked
increase in FDG metabolism in lesions that show a
response later on. Bender et al. [115] studied 10 patients
with irresectable liver metastases prior to and 72 h after
a single infusion of 5-FU and folinic acid. SUVs were
correlated with therapy outcome, with a follow-up of
at least 6 months. All metastases responding to therapy
(n = 6) exerted a statistically significant decrease
of FDG uptake (−22 ± 10%). Metastases showing
a short-term effect (duration of tumor reduction <3
months, n = 2) had a slightly diminished FDG uptake,
and in progressing metastases (n = 3) an enhanced
FDG uptake (13 ± 17%) was observed. Probably the
flare phenomenon does not play a role as early as
72 h after initiation of chemotherapy. These preliminary
data indicate that acute changes of glucose utilization
following a single application of chemotherapy seem to
be indicative for the final therapeutic outcome. More
recently, Dimitrakopoulou-Strauss et al. [116] examined
the ability of serial semiquantitative as well as quanti-
tative dynamic FDG-PET examinations in 28 patients to
predict response to second-line FOLFOX (5-FU, folinic
acid, and oxaliplatin) at baseline and after the first and
second cycle. The clinical response data, according to the
WHO classification, served as a standard of reference.
Even the first PET study (at baseline) was predictive
with respect to therapy outcome. The so-called fractal
dimension, a parameter that can be obtained from kinetic
analysis and may help to quantify tumor heterogeneity,
showed the best results and classified progressive disease
correctly in 90% of cases and stable disease in 75%
of cases at baseline. Furthermore, metastases with
a baseline SUV lower than 4.6 did not respond to
chemotherapy. The authors postulate that tumors with a
low FDG uptake often reveal an enhanced expression
of resistance genes. A low FDG uptake, particularly in
pretreated patients, may reflect an enhanced resistance to
chemotherapeutic drugs and is therefore associated with
a poor outcome of chemotherapy. In another study with
25 patients of similar characteristics Dimitrakopoulou-
Strauss et al. [117] examined the ability of serial FDG-
PET to predict chemotherapy response as reflected by
individual survival times. In this study, scans were
performed before initiation of therapy and after the first
and third cycle. They showed that a combination of
kinetic parameters of the first and the third scan provided
the best results for classification into a short or long
term survival class (defined as survival for less than 1
year or more than 1 year, respectively) and that even
an individual prognosis of survival could be achieved.
The authors feel that quantitative, dynamic FDG-PET
should be used preferentially for chemotherapy response
monitoring.
Conclusions
FDG-PET plays a pivotal role in the detection of
recurrent disease, the assessment of residual masses
after treatment, the localization of recurrence in patients
with an unexplained rise of serum CEA, and in staging
patients before surgical resection of local recurrence and
metastatic disease.
FDG-PET is emerging as a potentially valuable
technique in the prediction and evaluation of response
to radiotherapy, systemic therapy, and combinations
thereof. Correlation between changes in FDG uptake
and overall patient survival remains a very worthwhile
avenue of research to pursue. The preliminary findings
call for systematic inclusion of FDG-PET in therapeutic
trials to adequately position FDG-PET in treatment time
lines in order to change current therapeutic concepts
to individualized treatment of patients with advanced
colorectal cancer.
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